Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8417912 | 0.92 | MAPT (0.68) | CYP1A2CYP2C9CYP2C19MAPTMEN1 | |
| SCHEMBL14038429 | 0.89 | ALDH1A1 (0.61) | CYP1A2CYP2C9CYP2C19MAPTMEN1 | |
| SCHEMBL8397383 | 0.85 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19MAPTMEN1 | |
| SCHEMBL29761215 | 0.85 | KDM4E (0.79) | CYP1A2CYP2C9CYP2C19MAPTMEN1 | |
| SCHEMBL10876363 | 0.85 | KDM4E (0.79) | CYP1A2CYP2C9CYP2C19MAPTMEN1 | |
| SCHEMBL10490578 | 0.84 | MEN1 (0.56) | CYP1A2CYP2C9CYP2C19MAPTMEN1 | |
| SCHEMBL11077676 | 0.84 | THRB (0.56) | CYP1A2CYP2C9CYP2C19MAPTMEN1 | |
| SCHEMBL4612653 | 0.84 | TSHR (0.56) | CYP1A2CYP2C9MAPTALDH1A1TSHR | |
| SCHEMBL11655575 | 0.84 | TSHR (0.53) | CYP1A2CYP2C9CYP2C19MAPTMEN1 | |
| SCHEMBL30646245 | 0.84 | TSHR (0.53) | CYP1A2CYP2C9CYP2C19MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060111409-A1 | Medicament for treatment of diabetes | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-25 | — | — | US | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060089395-A1 | Nf-kb activation inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-0833203-B1 | Anthraquinone compounds | NIPPON CATALYTIC CHEM IND (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-5968688-A | RESINS AND DYES FOR COLOR FILTERS | NIPPON SHOKUBAI CO., LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| EP-0611811-B1 | RECORDING FLUID | MITSUBISHI CHEM IND (JP) | 1999-09-01 | — | — | EP | disclosed |
| EP-0844288-A2 | Recording liquid | MITSUBISHI KASEI CORPORATION (JP) | 1998-05-27 | — | — | EP | disclosed |
| EP-0844289-A2 | Recording liquid | MITSUBISHI KASEI CORPORATION (JP) | 1998-05-27 | — | — | EP | disclosed |
| EP-0833203-A1 | Color filter grade photosensitive resin coloring composition, and color filter using the same | NIPPON SHOKUBAI CO., LTD. (JP) | 1998-04-01 | — | — | EP | disclosed |
| US-5478384-A | Recording liquid | MITSUBISHI KASEI CORPORATION (JP) | 1995-12-26 | — | — | US | disclosed |
| EP-0611811-A1 | RECORDING FLUID | MITSUBISHI KASEI CORPORATION (JP) | 1994-08-24 | — | — | EP | disclosed |
| US-5278213-A | Low viscosity solution | ALLIED SIGNAL INC. (US) | 1994-01-11 | — | — | US | disclosed |
| EP-0056475-A2 | Pharmaceutical compositions | MERCK PATENT GmbH (DE) | 1982-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | NFKBIA, IKBKB, RELA | CYP1A2 3812/4885CYP2C9 4462/4885CYP2C19 4659/4885 |
| US-20060111409-A1 | Medicament for treatment of diabetes | XDH, SLC5A1, SLC5A2 | CYP1A2 1040/4885CYP2C9 3031/4885CYP2C19 2879/4885 |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | CYP1A2 631/4885CYP2C9 2244/4885CYP2C19 1303/4885 |
| US-20060122243-A1 | Antiallergic | EPX, NAT1, HNMT | CYP1A2 696/4885CYP2C9 2245/4885CYP2C19 1187/4885 |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAPT, TFEB, MAOA | CYP1A2 2043/4885CYP2C9 3673/4885CYP2C19 3948/4885 |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | NFATC1, AP1G1, ATF1 | CYP1A2 3409/4885CYP2C9 4580/4885CYP2C19 4710/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | CYP1A2 576/4885CYP2C9 1934/4885CYP2C19 1222/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | CYP1A2 589/4885CYP2C9 1984/4885CYP2C19 1171/4885 |
| US-20060089395-A1 | Nf-kb activation inhibitors | NFKBIA, IKBKB, NFRKB | CYP1A2 3089/4885CYP2C9 3863/4885CYP2C19 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.